Binita M. Kamath, Wen Ye, Nathan P. Goodrich, Kathleen M. Loomes, Rene Romero, James E. Heubi, Daniel H. Leung, Nancy B. Spinner, David A. Piccoli, Estella M. Alonso, Stephen L. Guthery, Saul J. Karpen, Cara L. Mack, Jean P. Molleston, Karen F. Murray, Philip Rosenthal, James E. Squires, Jeffrey Teckman, Kasper S. Wang, Richard Thompson, John C. Magee, Ronald J. Sokol, for the Childhood Liver Disease Research Network (ChiLDReN) – 22 January 2020 – Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder with cholestasis as a defining clinical feature.

Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang – 22 January 2020

Andrea Bisso, Marco Filipuzzi, Gianni Paolo Gamarra Figueroa, Giulia Brumana, Francesca Biagioni, Mirko Doni, Giorgia Ceccotti, Nina Tanaskovic, Marco Jacopo Morelli, Vera Pendino, Fulvio Chiacchiera, Diego Pasini, Daniela Olivero, Stefano Campaner, Arianna Sabò, Bruno Amati – 22 January 2020

Poh Hwa Ooi, Vera C. Mazurak, Kerry Siminoski, Ravi Bhargava, Jason Y. K. Yap, Susan M. Gilmour, Diana R. Mager – 22 January 2020 – Sarcopenia is a muscle disease characterized by reduced skeletal muscle mass (SMM), muscle strength, and physical performance. Reduced SMM has been identified in children after liver transplantation (LT), but no information related to muscle strength/physical performance or lifestyle factors contributing to sarcopenia is available.

21 January 2020

21 January 2020

Rohit Loomba, Brent A Neuschwander‐Tetri, Arun Sanyal, Naga Chalasani, Anna Mae Diehl, Norah Terrault, Kris Kowdley, Srinivasan Dasarathy, David Kleiner, Cynthia Behling, Joel Lavine, Mark Van Natta, Michael Middleton, James Tonascia, Claude Sirlin, for the NASH Clinical Research Network – 21 January 2020

Patrícia dos Santos Marcon, Angelo Zambam Mattos, Angelo Alves Mattos – 21 January 2020

Pir A. Shah, Daryl T.Y. Lau, Nicholas W. Russo, Robert S. Brown, Jessica L. Maiers, Robert E. Schwartz, Norihiro Imai, Tibor I. Krisko, Amaia Navarro‐Corcuera, Nidhi Jalan‐Sakrikar, Joseph F. Pisa, Arun B. Jesudian, Zaid H. Tafesh, Brett E. Fortune, Enis Kostallari – 21 January 2020

Isabel Cañon Reyes, Esteban Halac, Diego Aredes, Leandro Lauferman, Guillermo Cervio, Marcelo Dip, Julia Minetto, Hayellen Reijenstein, Veronica Meza, Maria Gole, Agustina Jacobo Dillon, Oscar Imventarza – 21 January 2020 – The most common indications for early liver retransplantation (eRe‐LT) are vascular complications and primary nonfunction (PNF). These patients are usually in a critical clinical condition that can affect their chances of survival. In fact, the survival of these patients is usually lower compared with the patients undergoing a first transplant.